BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

APAC Biotech IPOs of 2026: Who Listed, What It Raised, Where It Trades Now

How this list was built Scope. Every biotech initial public offering with a first trading day between 1 January and 24 September 2026 on five venu...

September 28, 2026 | Analysis

The 10 Deals That Defined APAC Biopharma in 2026

The biggest pharma deals of 2026 with an Asia-Pacific principal are easy to list and hard to rank. The ten on this page carry more than US$70 billion in he...

September 25, 2026 | Analysis

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

Skyhawk’s SKY-0515 Shows Significant Clinical Benefit in 15-Month Huntington’s Disease Study

The fifteen-month dataset represents the final analysis from the Phase 1/2 study At the Month 15 primary timepoint, SKY-0515-treated patients showed a +...

September 17, 2026 | Report

Harbour BioMed’s HBM9378 Shows Sustained Asthma Control with Twice-Yearly Dosing Potential

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...

September 10, 2026 | News

The Arbitrage Triangle

METHOD IN BRIEF Flow estimates come from published government statistics and press reporting of official material; no authority in the region publishes in...

September 09, 2026 | Analysis

Clover Biopharmaceuticals Reports Positive Phase II Results for RSV-hMPV-PIV3 Combination Vaccines

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differe...

September 08, 2026 | News

Where the Longevity Money Actually Goes

METHOD IN BRIEF Window: 1 January to 31 August 2026 for round-level claims, with full-year 2024 and 2025 figures for context. Attribution follows scientif...

September 07, 2026 | Analysis

Nobody Is the Payer

A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in ...

September 04, 2026 | Analysis

Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial

Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...

September 04, 2026 | News

The Biological Age Business

On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...

August 27, 2026 | Analysis

The Sarcopenia Definition Race: The Endpoint Is the Asset

In a category with no approvable indication anywhere in the world, whoever writes the endpoint definition controls who is eligible for a trial, what counts...

August 12, 2026 | Analysis

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

August 12, 2026 | News

Stay Connected